Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis

Atherosclerosis

Volumn 216, Issue 1, 2011, Pages 23-34

  Werner, Christian ^a   Gensch, Christoph ^a   Pöss, Janine ^a   Haendeler, Judith ^b   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Akt; Endothelial apoptosis; Pioglitazone; PPAR ; Telomerase; Vascular aging

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHECKPOINT KINASE 2; PIOGLITAZONE; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ISOLATION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; ULTRAVIOLET B RADIATION; UPREGULATION;

ANIMALS; AORTA; APOPTOSIS; CATTLE; CDC2 PROTEIN KINASE; CELL AGING; CELL SURVIVAL; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOPROTECTION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDANTS; OXIDATIVE STRESS; PHOSPHORYLATION; PPAR GAMMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TELOMERASE; TELOMERE; TELOMERIC REPEAT BINDING PROTEIN 2; THIAZOLIDINEDIONES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 79955532876     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.011     Document Type: Article

References (42)

1. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
2. Betteridge D.J. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol 2009, 23:675-679.
3. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
4. Brown J.D., Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115:518-533.
5. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106:523-531.
6. Gensch C., Clever Y.P., Werner C., Hanhoun M., Böhm M., Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007, 192:67-74.
7. Werner C., Kamani C.H., Gensch C., Böhm M., Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007, 56:2609-2615.
8. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004, 94:1168-1178.
9. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008, 102:283-294.
10. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005, 6:611-622.
11. Calado R.T, Young N.S. Telomere diseases. N Engl J Med 2009, 361:2353-2365.
12. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369:107-114.
13. Wong L.S, de Boer R.A., Samani N.J., van Veldhuisen D.J., van der Harst P. Telomere biology in heart failure. Eur J Heart Fail 2008, 10:1049-1056.
14. Wilson W.R., Herbert K.E., Mistry Y., et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 2008, 29:2689-2694.
15. Werner C., Hanhoun M., Widmann T., et al. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol 2008, 52:470-482.
16. Werner C, Fürster T., Widmann T., et al. Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. Circulation 2009, 120:2438-2447.
17. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
18. Poon S.S., Lansdorp P.M. Measurements of telomere length on individual chromosomes by image cytometry. Methods in cell biology: flow cytometry 2001, vol. 64. Academic Press, San Diego, CA, pp. 69-96, [chapter 33].
19. Debacq-Chainiaux F., Erusalimsky J.D., Campisi J., Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009, 4:1798-1806.
20. Marx N, Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
21. Voghel G., Thorin-Trescases N., Farhat N., et al. Chronic treatment with N-acetyl-cystein delays cellular senescence in endothelial cells isolated from a subgroup of atherosclerotic patients. Mech Ageing Dev 2008, 129:261-270.
22. Matsushita H., Chang E., Glassford A.J., Cooke J.P., Chiu C.P., Tsao P.S. eNOS activity is reduced in senescent human endothelial cells: preservation by hTERT immortalization. Circ Res 2001, 89:793-798.
23. Chen J., Patschan S., Goligorsky M.S. Stress-induced premature senescence of endothelial cells. J Nephrol 2008, 21:337-344.
24. Wang C.Y., Kim H.H., Hiroi Y., et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2009, 2:ra11.
25. Matthews C., Gorenne I., Scott S., et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 2006, 99:156-164.
26. Fuster J.J., Andres V. Telomere biology and cardiovascular disease. Circ Res 2006, 99:1167-1180.
27. Makino N., Maeda T., Oyama J., Higuchi Y., Mimori K. Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats. Am J Physiol Heart Circ Physiol 2009, 297:H2188-H2195.
28. Imanishi T., Kobayashi K., Kuroi A., Ikejima H., Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res 2008, 31:757-765.
29. Haendeler J., Hoffmann J., Diehl J.F., et al. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ Res 2004, 94:768-775.
30. Beliveau A., Yaswen P. Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 2007, 6:1284-1287.
31. Oh H., Wang S.C., Prahash A., et al. Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci USA 2003, 100:5378-5383.
32. Spallarossa P., Altieri P., Aloi C., et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol 2009, 297:H2169-H2181.
33. Kajstura J., Gurusamy N., Ogorek B., et al. Myocyte turnover in the aging human heart. Circ Res 2010, 107:1374-1386.
34. Dong W., Wang L., Chen X., Sun P., Wu Y. Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer. Dig Dis Sci 2010, 55:997-1003.
35. Dimmeler S., Vasa-Nicotera M. Aging of progenitor cells: limitation for regenerative capacity?. J Am Coll Cardiol 2003, 42:2081-2082.
36. van der Harst P., van der Steege G., de Boer R.A., et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 2007, 49:1459-1464.
37. Ornish D., Lin J., Daubenmier J., et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol 2008, 9:1048-1057.
38. Wang H.L., Akinci I.O., Baker C.M., et al. The intrinsic apoptotic pathway is required for lipopolysaccharide-induced lung endothelial cell death. J Immunol 2007, 179:1834-1841.
39. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
40. Thum T., Hoeber S., Froese S., et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res 2007, 100:434-443.
41. Büchner N., Altschmied J., Jakob S., Saretzki G., Haendeler J. Well-known signalling proteins exert new functions in the nucleus and mitochondria. Antioxid Redox Signal 2009.
42. Haendeler J., Drose S., Buchner N., et al. Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage. Arterioscler Thromb Vasc Biol 2009, 29:929-935.